Effect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion for Flexible Ureteroscope in Treating Renal Stones; A Prospective, Multicentre, Randomized Trial

Sponsor
Al-Azhar University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05833386
Collaborator
Benha University (Other), Alexandria University (Other), Cairo University (Other), Menoufia University (Other), Tanta University (Other)
2,000
1
2
39
51.2

Study Details

Study Description

Brief Summary

The ureteral access sheath (UAS) is an ancillary device widely used by urologists to facilitate fast, repeatable, and safe access to ureters and collecting systems; improve visibility; reduce the risk of infection by reducing intrarenal pressure; and protect ureters and scopes when extracting multiple stones during surgery.

Insertion of ureteric access sheath may be difficult due to tight ureter, so sometimes preoperative stenting might be needed. Silodosin is an α1A adrenoceptor with high affinity and selectivity for the ureteric muscle, which may reduce ureteral spasm.

Oral a1-blockers can reduce intraureteral pressure, and may reduce maximal ureteral access sheath insertion force.¹ Preoperative silodosin protects against significant ureteral injury related to UAS insertion during fURS and decreases postoperative pain level. Silodosin premedication might be an effective and safe technique to replace prestenting.²

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ureteral access sheath placement during flexible ureteroscope for renal stones
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion for Flexible Ureteroscope in Treating Renal Stones; A Prospective, Multicentre, Randomized Trial
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
May 1, 2026
Anticipated Study Completion Date :
Aug 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Silodosin group

all patients will receive oral silodosin 8 mg orally for 0ne week prior to surgery

Procedure: Ureteral access sheath placement during flexible ureteroscope for renal stones
Ureteral access sheath placement during flexible ureteroscope

Active Comparator: Non premedicated group

None of this group will receive alpha blocker prior to surgery

Procedure: Ureteral access sheath placement during flexible ureteroscope for renal stones
Ureteral access sheath placement during flexible ureteroscope

Outcome Measures

Primary Outcome Measures

  1. failure rate of UAS insertion during FURS [2 hours]

Secondary Outcome Measures

  1. Ureteral injuries after UAS insertion [3 hours]

    Ureter wall injury will be classified according to the following five grades: Grade 0: No lesion or only mucosal petechiae. Grade 1: Mucosal erosion or a mucosal flap without smooth muscle injury. Grade 2: Erosion involving the mucosa and smooth muscle but sparing the adventitia. Grade 3: Ureteral perforation involving the full thickness of the ureteral wall, including the adventitia. Grade 4: Total ureteral avulsion with a complete rupture of ureteral continuity.

  2. Post operative pain [12 hours after surgery]

    a visual analog scale (VAS) score (0 = no pain to 10 = excruciating pain) to indicate the intensity of postoperative pain 12 h after surgery.

  3. Complications related to the procedure [3 months]

    will be graded using the modified Clavien-Dindo classification system.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients with renal stones who will undergo flexible ureteroscopy and planned for using ureteral access sheath
Exclusion Criteria:
  • Paediatric age group (less than 18 year)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Urology department - AlAzhar university Cairo Egypt

Sponsors and Collaborators

  • Al-Azhar University
  • Benha University
  • Alexandria University
  • Cairo University
  • Menoufia University
  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mohamed Fawzy Abd Elfattah Salman, director, Al-Azhar University
ClinicalTrials.gov Identifier:
NCT05833386
Other Study ID Numbers:
  • pre-FURS sildosin
First Posted:
Apr 27, 2023
Last Update Posted:
Apr 27, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2023